NuWays puts SynBiotic rating under review, price target under review

• NuWays placed its recommendation on SynBiotic under review, citing a fundamentally changed investment case.
• Insolvencies, liquidations, and wind-downs across the portfolio cut the operating base, driven by weaker CBD demand and regulatory uncertainty.
• NuWays expects a narrower group centered on WEECO Pharma, with MH medical hemp and Ilesol as smaller remaining operations.
• Balance-sheet pressure and liquidity risk increased as the group relies heavily on WEECO for sales and cash generation.
• The firm withheld a 12-month target price pending audited accounts and clearer funding visibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynBiotic SE published the original content used to generate this news brief via EQS News (Ref. ID: rc_26620) on August 24, 2026, and is solely responsible for the information contained therein.